According to the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC, it is recommended to perform routine mutation tests for EGFR, BRAF, ERBB2, and MET as well as rearrangements in ALK, ROS1, and RET in all patients diagnosed with advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.